TrialClinical and translational science2021

Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers.

Desmond Y H Yap et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.